Hepatic circulatory diseases associated with chronic myeloid disorders

Clinics in Liver Disease

Volumn 6, Issue 4, 2002, Pages 909-931

  Poreddy, Vijayrama ^a   DeLeve, Laurie D ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN III; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 5; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DEFIBROTIDE; DIURETIC AGENT; FIBRINOLYTIC AGENT; GEMTUZUMAB OZOGAMICIN; LOW MOLECULAR WEIGHT HEPARIN; MYELOABLATIVE AGENT; PENTOXIFYLLINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; PROSTAGLANDIN E; PROTEIN C; PROTEIN S; PROTHROMBIN; PYRROLIZIDINE ALKALOID; TIOGUANINE; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; URETHAN; URSODEOXYCHOLIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; AMINOTRANSFERASE BLOOD LEVEL; ASCITES; BUDD CHIARI SYNDROME; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMICAL CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DOPPLER FLOWMETER; DRUG INFUSION; DRUG MEGADOSE; FLUID RETENTION; GENE MUTATION; HEPATIC ENCEPHALOPATHY; HEPATOMEGALY; HUMAN; HYPERBILIRUBINEMIA; HYPERCOAGULABILITY; LIVER BIOPSY; LIVER BLOOD FLOW; LIVER CIRCULATION; LIVER CIRRHOSIS; LIVER CONGESTION; LIVER CYST; LIVER HEMATOMA; LIVER HYPERPLASIA; LIVER NECROSIS; LIVER TRANSPLANTATION; LIVER VENOOCCLUSIVE DISEASE; LUNG EMBOLISM; MULTIPLE ORGAN FAILURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PARACENTESIS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; PELIOSIS HEPATIS; POLYCYTHEMIA VERA; PORTAL VEIN THROMBOSIS; PORTOSYSTEMIC ANASTOMOSIS; PROGNOSIS; PROTEIN C DEFICIENCY; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SODIUM RESTRICTION; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY; WEIGHT GAIN;

HEPATIC VEIN THROMBOSIS; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LIVER; LIVER CIRCULATION; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PELIOSIS HEPATIS; PORTAL VEIN; RISK FACTORS; VENOUS THROMBOSIS;

EID: 0036867318     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(02)00051-X     Document Type: Review

References (129)

1. Tefferi A, Solberg LA, Silverstein MN. A clinical update in polycythemia vera and essential thrombocythemia. Am J Med 2000;109:141-9.
2. Okuda H, Yamagata H, Obata H, et al. Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol 1995;22:1-9.
3. Okuda K, Kage M, Shrestha SM. Proposal of a new nomenclature for Budd-Chiari syndrome: Hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion. Hepatology 1998;28:1191-8.
4. Kage M, Arakawa M, Kojiro M, et al. Histopathology of membranous obstruction of the inferior vena cava in the Budd-Chiari syndrome. Gastroenterology 1992;102:2081-90.
5. Shrestha SM, Joshi BL, Shrestha S, et al. Cavographic study of inferior vena cava obstruction: Cavographic study of an early stage of obstruction of the hepatic portion of the inferior vena cava. J Gastroenterol Hepatol 2000;15:202-10.
6. Valla D, Casadevall N, Huisse MG, et al. Etiology of portal vein thrombosis in adults: A prospective evaluation of primary myeloproliferative disorders. Gastroenterol 1988;94:1063-9.
7. Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorder and hepatic vein thrombosis: A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 1985;103:329-34.
8. De Stefano V, Teofili L, Leone G, et al. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997;23:411-8.
9. Henderson JM, Warren WD, Millikan Jr WJ, et al. Surgical options, hematologic evaluation, and pathologic changes in Budd-Chiari syndrome. Am J Surg 1990;159:41-50.
10. Orloff MJ, Daily PO, Orloff SL, et al. A 27-year experience with surgical treatment of Budd-Chiari syndrome. Ann Surg 2000;232:340-52.
11. Zeitoun G, Escolano S, Hadengue A, et al. Outcome of Budd-Chiari syndrome: A multivariate analysis of factors related to survival including surgical portasystemic shunting. Hepatology 1999;30:84-9.
12. Slakey DP, Klein AS, Venbrux AC, et al. Budd-Chiari syndrome: Current management options. Ann Surg 2001;233:522-7.
13. Campbell Jr. DA, Rolles K, Jamieson N, et al. Hepatic transplantation with perioperative and long term anticoagulation as treatment for Budd-Chiari syndrome. Surg Gynecol Obstet 1988;166:511-8.
14. Thompson EN, Sherlock S. The aetiology of portal vein thrombosis with particular reference to the role of infection and exchange transfusion. Q J Med 1964;132:465-79.
15. Boles Jr. ET, Weiss Jr. WE, Birken G. Extrahepatic portal hypertension in children: Long term evaluation. Am J Surg 1986;151:734-9.
16. Webb LJ, Sherlock S. The etiology, presentation and natural history of extrahepatic portal venous obstruction. Q J Med 1979;192:627-39.
17. Okuda K, Ohnishi K, Kimura K. Incidence of portal vein thrombosis liver cirrhosis: An angiographic study in 708 patients. Gastroenterology 1988;89:279-86.
18. Witte CL, Brewer ML, Witte MH, et al. Protean manifestations of pylethrombosis: A review of thirty-four patients. Ann Surg 1985;202:191-202.
19. Condat B, Pesslore F, Hillaire S, et al. Current outcome of portal vein thrombosis in adults: Risk and benefit of anticoagulant therapy. Gastroenterology 2001;120:490-7.
20. Valla D, Condat B. Portal vein thrombosis in adults: Pathophysiology, pathogenesis, and management. J Hepatol 2000;32:865-71.
21. Denninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors. Hepatology 2000;31:587-91.
22. Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: Results of a case-control study. Blood 2000;96:2364-8.
23. Belli L, Sansalone CV, Aseni P, et al. Portal vein thrombosis in cirrhotics: A retrospective analysis. Ann Surg 1986;203:286-91.
24. Bick RL. Coagulation abnormalities in malignancy. Semin Thromb Hemost 1992;18:353-72.
25. Bernades P, Baetz A, Levy P, et al. Splenic and portal venous obstruction in chronic pancreatitis: A prospective longitudinal study of a medical-surgical series of 266 patients. Dig Dis Sci 1992;37:340-6.
26. Cohen J, Edelman R, Chopra S. Portal vein thrombosis: A review. Am J Med 1991;92:173-82.
27. Alvarez F, Bernard O, Brunelle F, et al. Portal obstruction in children. I. Clinical investigation and hemorrhage risk. J Pediatr 1983;103:696-702.
28. Mathieu D, Vasile N, Grenier P. Portal thrombosis: Dynamic CT features and course. Radiology 1985;154:737-41.
29. Ganger DR, Klapman JB, McDonald V, et al. Transjugular intrahepatic portosystemic shunt (TIPS) for Budd-Chiari syndrome or portal vein thrombosis. Am J Gastroenterol 1999;94:603-8.
30. Cherukuri R, Haskal ZJ, Naji A, et al. Percutaneous thrombolysis and stent placement for the treatment of portal vein thrombosis after liver transplantation: Long-term follow-up. Transplantation 1998;65:1124-6.
31. Ciccarelli O, Goffette P, Laterre PF, et al. Transjugular intrahepatic portosystemic shunt approach and local thrombolysis for treatment of early posttransplant portal vein thrombosis. Transplantation 2001;72:159-61.
32. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (venoocclusive disease). Semin Liver Dis 2002;22:623-38.
33. Bras G, Jeliffe DB, Stuart KL. Veno-occlusive disease of the liver with non-portal type of cirrhosis occurring in Jamaica. Arch Pathol 1954;57:285-300.
34. McFarlane AL, Branday W. Hepatic enlargement with ascitic children. BMJ 1945;1:838-40.
35. Selzer G, Parker RGF. Senecio poisoning exhibiting as Chiari's syndrome: A report on twelve cases. Am J Pathol 1950;27:885-907.
36. Willmot FC, Robertson GW. Senecio disease, or cirrhosis of the liver due to senecio poisoning. Lancet 1920;2:848-9.
37. Azoulay D, Castaing D, Lemoine A, et al. Successful treatment of severe azathioprine-induced hepatic veno-occlusive disease in a kidney-transplanted patient with transjugular intrahepatic portosystemic shunt. Clin Nephrol 1998;50:118-22.
38. Eisenhauer T, Hartmann H, Rumpf KW, et al. Favourable outcome of hepatic veno-occlusive disease in a renal transplant patient receiving azathioprine, treated by portacaval shunt: Report of a case and review of the literature. Digestion 1984;30:185-90.
39. Haboubi NY, Ali HH, Whitwell HL, et al. Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: Light microscopy and ultrastructural observations. Am J Gastroenterol 1988;83:256-61.
40. Katzka DA, Saul SH, Jorkasky D, et al. Azathioprine and hepatic venocclusive disease in renal transplant patients. Gastroenterology 1986;90:446-54.
41. Liano F, Moreno A, Matesanz R, et al. Veno-occlusive hepatic disease of the liver in renal transplantation: Is azathioprine the cause? Nephron 1989;51:509-16 [see comments].
42. Mion F, Cloix P, Biollot O, et al. Venocclusive disease after liver-transplantation-association of acute cellular rejection and toxicity of azathioprine. Gastroenterol Clin Biol 1993;17:863-7.
43. Read AE, Wiesner RH, LaBrecque DR, et al. Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med 1986;104:651-5.
44. Sterneck M, Wiesner R, Ascher N, et al. Azathioprine hepatotoxicity after liver transplantation. Hepatology 1991;14:806-10.
45. DeLeve LD. Liver function and hepatotoxicity in cancer. In: Holland JF, Frei E, Bast Jr RC, Kufe DW, Pollock RE, Weichselbaum RR, editors. Cancer Medicine. 5th Edition. Hamilton, ON, Canada: BC Dekker; 2000;151:2346-58.
46. Giles FJ, Kantarjian HM, Komblau SM, et al. Mylotarg (Gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001;92:406-13.
47. Rajvanshi P, Shulman HM, Sievers EL, et al. Hepatic sinusoidal obstruction following Gemtuzumab ozogamicin (Mylotarg). Blood 2002;2310-4.
48. Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998;92:3599-604.
49. Jones RJ, Lee KSK, Beschorner WE, et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987;44:778-83.
50. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation - A cohort study of 355 patients. Ann Intern Med 1993;118:255-67.
51. McDonald GB, Sharma P, Matthews DE, et al. Veno-occlusive disease of the liver after bone marrow transplantation: Diagnosis,incidence and predisposing factors. Hepatology 1984;4:116-22.
52. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-400.
53. McDonald GB, Ren S, Bouvier ME, et al. Venocclusive disease of the liver and cyclophosphamide pharmacokinetics: A prospective study in marrow transplant patients [abstract]. Hepatology 1999;30:314A.
54. Frickhofen N, Wiesneth M, Jainta C, et al. Hepatitis C infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994;83: 1998-2004.
55. Ljungman P, Hagglund H, Lonnqvist B, et al. Hepatitis C virus as a risk factor for the development of veno-occlusive disease of the liver [letter]. Blood 1994;84:1349-50.
56. Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection and bone marrow transplantation: A cohort study with 10-year follow-up. Hepatology 1999;29:1893-9.
57. Hagglund H, Remberger M, Klaesson S, et al. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998;92:4568-72.
58. Shulman HM, Fisher LB, Schoch HG, et al. Venoocclusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms. Hepatology 1994;19:1171-80.
59. DeLeve LD. Dacarbazine toxicity in murine liver cells: A novel model of hepatic endothelial injury and glutathione defense. J Pharmacol Exp Ther 1994;268:1261-70.
60. DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation. Hepatology 1996;24:830-7.
61. DeLeve LD, Wang X, Kuhlenkamp JF, et al. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: The role of glutathione and relevance to hepatic venooclusive disease. Hepatology 1996;23:589-99.
62. DeLeve LD, McCuskey RS, Wang X, et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 1999;29:1779-91.
63. DeLeve LD, Ito Y, Machen NW, et al. Embolization by sinusoidal lining cells causes the congestion of hepatic venoocclusive disease. Gastroenterology 2000;118:A2345.
64. DeLeve LD, Wang X. Decrease in nitric oxide production contributes to hepatic venoocclusive disease. Hepatology 1999;30:218A.
65. Brooks SEH, Miller CG, McKenzie K, et al. Acute veno-occlusive disease of the liver. Arch Pathol 1970;89:507-20.
66. Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation-immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987;127:549-58.
67. Lee JL, Gooley T, Bensinger W, et al. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: Incidence, risk factors, and outcome. Biol Blood Marrow Transplant 1999;5:306-15.
68. Toh HC, McAfee SL, Sackstein R, et al. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 1999;24:891-5.
69. Costa F, Choy CG, Seiter K, et al. Hepatic outflow obstruction and liver failure due to leukemia cell infiltration in chronic lymphocytic leukemia. Leuk Lymphoma 1998;30:403-10.
70. Vukelja SJ, Baker WJ, Jeffreys P, et al. Nonbacterial thrombotic endocarditis clinically mimicking veno-occlusive disease of the liver complicating autologous bone marrow transplantation. Am J Clin Oncol 1992;15:500-2.
71. Blostein MD, Paltiel OB, Thibault A, et al. A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation. Bone Marrow Transplant 1992;10:439-43.
72. Shulman HM, McDonald GB, Matthews D, et al. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 1980;79:1178-91.
73. Strasser SI, McDonald SJ, Schoch HG, et al. Severe hepatocellular injury after hematopoietic cell transplant: Incidence and etiology in 2136 consecutive patients [abstract]. Hepatology 2000;32:299A.
74. Ganem G, Saint-Marc Girardin MF, Kuentz M, et al. Venoocclusive disease of the liver after allogeneic bone marrow transplantation in man. Int J Radiat Biol Phys 1988;14:879-84.
75. McDonald GB, Sharma P, Matthews DE, et al. The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation. Transplantation 1985;36:603-8.
76. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995;85:3005-20.
77. Locasciulli A, Bacigalupo A, Alberti A, et al. Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation. Transplantation 1989;48:68-72.
78. Méresse V, Hartmann O, Vassal G, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: A study in 136 children. Bone Marrow Transplant 1992;10:135-41.
79. Demirer T, Buckner CD, Appelbaum FR, et al. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant 1996;17:491-5.
80. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989;25:55-61.
81. Hassan M, Ehrsson H, Ljungman P. Aspects conceming busulfan pharmacokinetics and bioavailability. Leuk Lymphoma 1996;22:395-407.
82. Ljungman P, Hassan M, Bekassy AN, et al. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1997;20:909-13.
83. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: Does it improve clinical outcome? Clin Pharmacokinet 2000;39:155-65.
84. Schuler U, Schroer S, Kuhnle A, et al. Busulfan pharmacokinetics in bone marrow transplant patients: Is drug monitoring warranted? Bone Marrow Transplant 1994;14:759-65.
85. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation. Blood 1997;89:3055-60.
86. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 1998;20:543-9.
87. Attal M, Huguet F, Rubie H, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial. Blood 1992;79:2834-40.
88. Rosenthal J, Sender L, Secola R, et al. Phase 11 trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Bone Marrow Transplant 1996;18:185-91.
89. Essell JH, Schroeder MT, Harman GS, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:975-81.
90. Osahi K, Tanabe J, Watanabe R, et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic venoocclusive disease after stem cell transplantation. Am J Hematol 2000;64:32-8.
91. Bearman SI, Shen DD, Hinds MS, et al. A phase-I phase-II study of prostaglandin El for the prevention of hepatic venoocclusive disease after bone marrow transplantation. Br J Haematol 1993;84:724-30.
92. Clift RA, Bianco JA, Appelbaum FR, et al. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 1993;82:2025-30.
93. Ferrà C, de Sanjosé S, Lastra CF, et al. Pentoxyfylline, ciprofloxacin, and prednison failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications. Bone Marrow Transplant 1997;20:1075-80.
94. Gluckman E, Joviet I, Scrobohaci ML, et al. Use of prostaglandin El for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol 1990;74:277-81.
95. Marsa-Vila L, Gorin NC, Laporte JP, et al. Prophylactic heparin does not prevent liver venoocclusive disease following autologous bone marrow transplantation. Eur J Haematol 1991;47:346-54.
96. Stockschläder M, Kalhs P, Peters S, et al. Intravenous pentoxyfylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1993;12:357-62.
97. Rubenfeld GD, Crawford SW. Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: A case for evidence-based guidelines. Ann Intern Med 1996;125:625-33.
98. Wingard JR, Mellits ED, Jones RJ, et al. Association of hepatic veno-occlusive disease with interstitial pneumonitis in bone marrow recipients. Bone Marrow Transplant 1989;4:685-9.
99. Zager RA, O'Quigley J, Zager BK, et al. Acute renal failure following bone marrow transplantation: A retrospective study of 272 patients. Am J Kidney Dis 1989;13:210-6.
100. Baglin TP. Veno-occlusive disease of the liver complicating bone marrow transplantation. Bone Marrow Transplant 1994;13:1-4.
101. Bearman SI, Lee JL, Barón AE, et al. Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997;89:1501-6.
102. Kulkarni S, Rodriguez M, Lafuente A, et al. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD). Bone Marrow Transplant 1999;23:803-7.
103. Abbate R, Gori AM, Martini F, et al. Defibrotide reduces monocyte PA1-2 and procoagulant activity. Semin Thromb Hemost 1995;21:245-50.
104. Berti F, Rossoni G, Della Bella D, et al. Nitric oxide and prostacyclin influence coronary vasomotor tone in perfused rabbit heart and modulate endothelin-I activity. J Cardiovasc Pharmacol 1993;22:321-6.
105. Biagi G, Legnani C, Rodorigo G, et al. Modulation of arachidonate metabolite generation in human blood by oral defibrotide. Arzneimittelforschung 1991;41:511-4.
106. Bianchi G, Barone D, Lanzarotti E, et al. Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Eur J Pharmacol 1993;238:327-34.
107. Klocking HP. Acute t-PA release by defibrotide. Thromb Res 1992;66:779-85.
108. Lefer AM, Aoki N, Mulloy D. Coronary endothelium-protective effects of defibrotide in ischaemia and reperfusion. Naunyn-Schmiedebergs Archives of Pharmacology 1990;341:246-50.
109. Masini E, Lupini M, Mugnai L, et al. Polydeoxyribonucleotides and nitric oxide release from guinea-pig hearts during ischaemia and reperfusion. Br J Pharmacol 1995;115:629-35.
110. Pellegatta F, Lu Y, Radaelli A, et al. Drug-induced in vitro inhibition of neutrophil-endothelial cell adhesion. Br J Pharmacol 1996;118:471-6.
111. Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionate-use study. Br J Haematol 2000;111:1122-9.
112. Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-risk population. Blood 1998;92:737-44.
113. Azoulay D, Castaing D, Lemoine A, et al. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant 2000;25:987-92.
114. Rajvanshi P, McDonald GB. Expanding the use of transjugular intrahepatic portosystemic shunts for veno-occlusive disease. Liver Transplant 2001;7:154-9.
115. Zenz T, Rössle M, Bertz H, et al. Severe veno-occlusive disease after allogeneic bone marrow or peripheral stem cell transplantation-role of transjugular intrahepatic portosystemic shunt (TIPS). Liver 2001;21:31-6.
116. Gane E, Portmann B, Saxena R, et al. Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology 1994;20:88-94.
117. Mion F, Napoleon B, Berger F, et al. Azathioprine induced liver disease: Nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. Gut 1991;32:715-7.
118. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: A report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990;11(5):787-97.
119. Nakanuma Y. Nodular regenerative hyperplasia of the liver: Retrospective survey in autopsy series. J Clin Gastroenterol 1990;12:460-5.
120. Wanless IR, Godwin TA, Allen F, et al. Nodular regenerative hyperplasia of the liver in hematologic disorders: A possible response to obliterative portal venopathy. A morphometric study of nine cases with a hypothesis on the pathogenesis. Medicine (Baltimore) 1980;59(5):367-79.
121. Shimamatsu K, Wanless IR. Role of ischemia in causing apoptosis, atrophy, and nodular hyperplasia in human liver. Hepatology 1997;26:343-50.
122. Nakanuma Y, Ohta G, Sasaki K. Nodular regenerative hyperplasia of the liver associated with polyarteritis nodosa. Arch Pathol Lab Med 1984;108:133-5.
123. Young ID, Segura J, Ford PM, et al. The pathogenesis of nodular regenerative hyperplasia of the liver associated with rheumatoid vasculitis. J Clin Gastroenterol 1992;14:127-31.
124. Wanless IR, Solt LC, Kortan P, et al. Nodular regenerative hyperplasia of the liver associated with macroglobulinemia: A clue to the pathogenesis. Am J Med 1981;70:1203-9.
125. Snover DC, Weisdorf S, Bloomer J, et al. Nodular regenerative hyperplasia of the liver following bone marrow transplantation. Hepatology 1989;9:443-8.
126. Radomski JS, Chojnacki KA, Moritz MJ, et al. Results of liver transplantation for nodular regenerative hyperplasia. Am Surg 2000;66:1067-70.
127. Goerdt S, Sorg C. Endothelial heterogeneity and the acquired immunodeficiency syndrome: A paradigm for the pathogenesis of vascular disorders. Clin Invest 1992;70:89-98.
128. Scoazec JY, Marche C, Girard PM, et al. Peliosis hepatis and sinusoidal dilation during infection by the human immunodeficiency virus (HIV): An ultrastructural study. Am J Pathol 1988;131:38-47.
129. Leong SS, Cazen RA, Yu GS, et al. Abdominal visceral peliosis associated with bacillary angiomatosis: Ultrastructural evidence of endothelial destruction by bacilli. Arch Pathol Lab Med 1992;116:866-71.